EUCTR2005-003945-16-LV进行中（未招募）不适用
An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients - Phase II study of paclitaxel plus lapatinib in patients with ErbB2-amplified metastatic breast cance
GlaxoSmithKline R&D Ltd0 个研究点目标入组 56 人开始时间: 2006年2月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Able to give signed informed consent
- •- Female, aged >=18years; if of child-bearing potential, the patient must have a negative serum pregnancy test and agree to use a protocol-defined acceptable method of birth control
- •- Histologically-confirmed Stage IV invasive breast cancer; where the disease is restricted to a solitary lesion, the neoplastic nature should be confirmed
- •- Patients with ER+ and/or PR+ disease or of unknown status will only be included if: they have symptomatic visceral disease requiring chemotherapy; the disease is rapidly progressing or life-threatening; the patient has received endocrine therapy but is no longer benefiting from this therapy
- •- Documented amplification of ErbB2 by FISH in primary or metastatic tumour tissue
- •- If prior taxane received in the adjuvant or neoadjuvant setting, disease progression must have occurred >=12months after completion of this treatment
- •- Measurable lesions according to RECIST
- •- Radiotherapy prior to start of study medication is allowed to a limited area if not the sole site of disease. Patients must have completed radiation treatment and recovered from all associated toxicities
- •- Bisphosphonate therapy for bone metastases is allowed provided this treatment was initiated before statrting study medication. Prophylactic bisphosphonate therapy is not permitted, except for osteoporosis.
- •- CNS metastases must be stable for at least 3months; patients with leptomeningeal involvement are only eligible if not taking oral steroids or enzyme-inducing anticonvulsants
- •- Patientys must have cardiac ejection fraction within the institutional range of normal by ECHO or MUGA. Patients with known history of uncontrolled or symptomatic angina, arrhythmias or CHF are not eligible.
- •- ECOG performance status 0-1
- •- Life expectancy >=3months
- •- Able to swallow and retain oral medication
- •- New or archived tumour tissue must be available for analysis
- •- Patients must complete all screening assessments per-protocol
- •- Patients must have adequate organ function as defined in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnant or lactating
- •- Received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy for metastatic disease
- •- Prior therapy with ErbB1 and/or ErbB2 inhibitors
- •- Concurrent anti-cancer therapy while taking study medication
- •- Unresolved or unstable, serious toxicity from prior administration of another IMP or cancer treatment
- •- >= Grade 2 peripheral neuropathy
- •- Malabsorption syndrome, disease significantly affecting GI function, or resection of stomach or small bowel. Patients with ulcerative colitis will be excluded.
- •- History of other malignancy (unless disease-free for >=5years, or history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma)
- •- Concurrent disease or condition that would make the patient inappropriate for participation in the study
- •- Active or uncontrolled infection
- •- Any condition that prohibits understanding or rendering of informed consent
- •- History of uncontrolled or symtomatic angina, arrhythmias or CHF
- •- Concurrent treatment with an IMP or participation in another clinical trial involving investigational agents
- •- Use of investigational drug within 30days or five half-lives, whichever is longer, prior to first dose of study medication
- •- Known hypersensitivity reaction or idiosyncracy to drugs chemically related to lapatinib or excipients, or related to paclitaxel or excipients
研究者
相似试验
尚未招募
不适用
Phase II study of acalabrutinib and rituximab in patients with mentle cell lymphoma (MCL)KCT0007647Samsung Medical Center80
进行中（未招募）
不适用
?A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-ITOVARTIS FARMA48
进行中（未招募）
不适用
A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-DEovartis Pharma Services AG48
进行中（未招募）
1 期
A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.0Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-BEovartis Pharma Services AG48
进行中（未招募）
1 期
A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing anticonvulsant drugs (EIACDs).progressive glioblastoma multiforme (GBM) following failure of front-line therapy defined to include surgery, radiotherapy and exposure to temozolomide chemotherapy regimen.EUCTR2005-002603-16-DKovartis Pharma Services AG110